Editor’s Note: Tax season is here, and we have a special way for you to take advantage.

On Wednesday, March 19 at 2 p.m. EST, we’re going live with our friends at Prime Corporate Services.

We’ll be showing you how to save money on your tax bill, plus how to write off expenses from your trading income.

The event is completely FREE.

Click here to sign up.

– Ryan Fitzwater, Publisher

Last month, I told War Room members I’ve been looking at Moderna (MRNA) for a potential trade.

But I was hesitant to recommend an outright trade for one key reason.

You see… there’s been a lot of blowback surrounding the pharma company over the last six months.

Since COVID, Moderna got labeled a “vaccine” company. And with Republicans taking over the White House in January, the narrative has shifted to the negative as controversial “anti-vaccine activist” Robert F. Kennedy Jr. assumed the role of secretary of health.

But political strife aside – there are a lot of reasons to like Moderna right now.

The truth is…

Moderna is much more than a vaccine stock.

For example, it’s currently working on a solution to avian flu. It’s also working with Merck on a cancer vaccine. So there are multiple potential catalysts working in its favor right now.

And with so much “anti-vaccine sentiment” currently, the stock is nearing all-time lows.

But that’s exactly the time you should be looking at a trade.

Take a look at the chart below.

As you’ll see, Moderna was at “COVID era” highs around mid 2021.

Now it’s fallen back to $34 a share.

But with the current catalysts in avian flu and cancer vaccines working for it, I believe the stock could be in for a big move.

More catalysts for MRNA

I also recently saw something that I love to see on MRNA.

Earlier this month – two insiders at Moderna bought shares. Now, that’s not a huge eye-opener since insiders buy stock all the time.

However, in this case one insider bought $1 million worth of stock, and another insider bought $5 million worth of stock.

Those are big numbers.

Insiders also bought Merck and Pfizer a month ago.

And here’s one great thing about these pharmaceutical companies…

All of them are subject to headline risk – meaning you can use a two-pronged approach to trading them. For example, my colleague Bryan Bottarelli recently used a short-term trade strategy on MRNA last week. He closed a 31% winner in less than 1 trading day.

But because of the long-term catalysts for Moderna, you can also use my long-play strategies as well. So there are multiple ways to play it.

Action Plan: With a big dip in price since COVID and multiple catalysts working, I believe MRNA is a stock worth keeping on your radar.

If you want to see exactly how I’m playing companies like MRNA, I invite you to join Bryan and I in The War Room. So far in 2025, we have an 81% win rate, and last week we closed 9-of-11 trades for winners despite the shaky markets.

Click here to see how we navigated shaky markets like these with great success in the past.